	Efectivo Y Equivalentes		Fecha
Acadia Pharmaceuticals	USD 819.69M	27.33M	2025-12
Agios Pharmaceuticals	USD 89.13M	3.58M	2025-12
Alnylam Pharmaceuticals	USD 1.66B	167M	2025-12
Amarin	USD 122.8M	25.08M	2025-09
Amgen	USD 9.13B	316M	2025-12
Baxter International	USD 1.97B	240M	2025-12
Cara Therapeutics	USD 20.65M	13.57M	2025-06
Cytokinetics	USD 122.52M	102.95M	2025-12
DBV Technologies	USD 69.84M	33.37M	2025-09
Eli Lilly	USD 7.27B	2.52B	2025-12
Esperion Therapeutics	USD 92.45M	6.39M	2025-09
Halozyme Therapeutics	USD 133.82M	285.84M	2025-12
Intrexon	USD 9.34M	1.77M	2024-06
Ionis Pharmaceuticals	USD 2.68B	437M	2025-12
MannKind	USD 74.88M	52.51M	2025-12
Minerva Neurosciences	USD 12.29M	2.96M	2025-09
Nektar Therapeutics	USD 41.03M	1.96M	2025-09
Pfizer	USD 1.34B	295M	2025-09
Rigel Pharmaceuticals	USD 48.53M	4.87M	2025-09
United Therapeutics	USD 1.56B	217M	2025-12
Vanda Pharmaceuticals	USD 84.85M	14.83M	2025-12

Halozyme Therapeutics Efectivo Y Equivalentes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.